Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation
Open Access

Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers

Stefan A. Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L. Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, Jeremie Calais, Hans-Ulrich Kauczor, Dirk Jaeger, Juergen Debus, Uwe Haberkorn and Frederik L. Giesel
Journal of Nuclear Medicine November 2023, 64 (11) 1712-1720; DOI: https://doi.org/10.2967/jnumed.123.266046
Stefan A. Koerber
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;
2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;
3Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany;
4Department of Radiation Oncology, Barmherzige Brueder Hospital Regensburg, Regensburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Röhrich
5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;
6Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leon Walkenbach
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakob Liermann
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;
2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter L. Choyke
7Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Fink
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;
2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathrin Schroeter
5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna-Maria Spektor
5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Herfarth
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;
2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;
3Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Walle
8Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany;
9Clinical Cooperation Unit Virotherapy, German Cancer Research Center, Heidelberg, Germany;
10German Cancer Consortium, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
11Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Ulrich Kauczor
12Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Jaeger
6Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juergen Debus
1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;
2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;
3Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany;
10German Cancer Consortium, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;
13Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik L. Giesel
5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;
8Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany;
14Department of Nuclear Medicine, Medical Faculty, Heinrich-Heine University, University Hospital Düsseldorf, Düsseldorf, Germany; and
15Institute for Radiation Sciences, Osaka University, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 11 1712-1720
DOI 
https://doi.org/10.2967/jnumed.123.266046
PubMed 
37678928

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 23, 2023
  • Revision received August 1, 2023
  • Published online November 2, 2023.

Article Versions

  • previous version (September 7, 2023 - 06:29).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

  1. Stefan A. Koerber*,1,2,3,4,
  2. Manuel Röhrich*,5,6,
  3. Leon Walkenbach1,
  4. Jakob Liermann1,2,
  5. Peter L. Choyke7,
  6. Christoph Fink1,2,
  7. Cathrin Schroeter5,
  8. Anna-Maria Spektor5,
  9. Klaus Herfarth1,2,3,
  10. Thomas Walle8,9,10,
  11. Jeremie Calais11,
  12. Hans-Ulrich Kauczor12,
  13. Dirk Jaeger6,
  14. Juergen Debus1,2,3,10,
  15. Uwe Haberkorn5,13 and
  16. Frederik L. Giesel5,8,14,15
  1. 1Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany;
  2. 2National Center of Radiation Oncology, Heidelberg Institute of Radiation Oncology, Heidelberg, Germany;
  3. 3Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany;
  4. 4Department of Radiation Oncology, Barmherzige Brueder Hospital Regensburg, Regensburg, Germany;
  5. 5Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany;
  6. 6Department of Nuclear Medicine, Mainz University Hospital, Mainz, Germany;
  7. 7Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland;
  8. 8Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany;
  9. 9Clinical Cooperation Unit Virotherapy, German Cancer Research Center, Heidelberg, Germany;
  10. 10German Cancer Consortium, Heidelberg, Germany;
  11. 11Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California;
  12. 12Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany;
  13. 13Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany;
  14. 14Department of Nuclear Medicine, Medical Faculty, Heinrich-Heine University, University Hospital Düsseldorf, Düsseldorf, Germany; and
  15. 15Institute for Radiation Sciences, Osaka University, Osaka, Japan
  1. For correspondence or reprints, contact Manuel Röhrich (manuel.roehrich{at}med.uni-heidelberg.de).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 19 Citations
  • 19 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides
    Richard P. Baum, Emil Novruzov, Tianzhi Zhao, Lukas Greifenstein, Vivianne Jakobsson, Elisabetta Perrone, Aditi Mishra, Aleksandr Eismant, Kriti Ghai, Ortwin Klein, Bastian Jaeschke, Daniel Benz-Zils, Jens Cardinale, Yuriko Mori, Frederik L. Giesel, Jingjing Zhang
    Seminars in Nuclear Medicine 2024 54 4
  • Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)
    Yuriko Mori, Emil Novruzov, Dominik Schmitt, Jens Cardinale, Tadashi Watabe, Peter L. Choyke, Abass Alavi, Uwe Haberkorn, Frederik L. Giesel
    npj Imaging 2024 2 1
  • Diagnostic Potential of Supplemental Static and Dynamic68Ga-FAPI-46 PET for Primary18F-FDG–Negative Pulmonary Lesions
    Manuel Röhrich, Johanna Daum, Ewgenija Gutjahr, Anna-Maria Spektor, Frederik M. Glatting, Yasemin Aylin Sahin, Hans Georg Buchholz, Jorge Hoppner, Cathrin Schroeter, Eleni Mavriopoulou, Kai Schlamp, Matthias Grott, Florian Eichhorn, Claus Peter Heußel, Hans Ulrich Kauczor, Michael Kreuter, Frederik Giesel, Mathias Schreckenberger, Hauke Winter, Uwe Haberkorn
    Journal of Nuclear Medicine 2024 65 6
  • Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma or a Metaphor for Heterogeneity: From Single-Cell Analysis to Whole-Body Imaging
    Rita Saúde-Conde, Ayça Arçay Öztürk, Kosta Stosic, Oier Azurmendi Senar, Julie Navez, Christelle Bouchart, Tatjana Arsenijevic, Patrick Flamen, Jean-Luc Van Laethem
    Biomedicines 2024 12 3
  • FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?
    Irene García Megías, Ludmila Santiago Almeida, Adriana K. Calapaquí Terán, Kim M. Pabst, Ken Herrmann, Francesco Giammarile, Roberto C. Delgado Bolton
    Annals of Nuclear Medicine 2025 39 5
  • The Evolving Role of Novel Imaging Techniques for Radiotherapy Planning
    D.J. Noble, R. Ramaesh, M. Brothwell, T. Elumalai, T. Barrett, A. Stillie, C. Paterson, T. Ajithkumar
    Clinical Oncology 2024 36 8
  • [18F]F-FAPI-42 PET dynamic imaging characteristics and multiparametric quantification of lung cancer: an exploratory study using uEXPLORER PET/CT
    Lijuan Wang, Xingzhu Pan, Shimin Ye, Yanchao Huang, Meng Wang, Li Chen, Kemin Zhou, Yanjiang Han, Hubing Wu
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 5
  • First Clinical Experience of 68Ga-FAPI PET/CT in Tertiary Cancer Center: Identifying Pearls and Pitfalls
    Akram Al-Ibraheem, Ahmed Saad Abdlkadir, Ula Al-Rasheed, Dhuha Al-Adhami, Feras Istatieh, Farah Anwar, Marwah Abdulrahman, Rula Amarin, Issa Mohamad, Asem Mansour
    Diagnostics 2025 15 2
  • Comparative analysis of two timepoints on [18F]FAPI-42 PET/CT in various cancers
    Xingyu Mu, Biyun Mo, Jie Qin, Zuguo Li, Weixia Chong, Yulong Zeng, Lu Lu, Lei Zhang, Wei Fu
    European Journal of Hybrid Imaging 2023 7 1
  • FAPI PET in the Management of Lung Tumors
    Anne-Leen Deleu, Qaid Ahmed Shagera, Sophie Veldhuijzen van Zanten, Patrick Flamen, Olivier Gheysens, Hubertus Hautzel
    Seminars in Nuclear Medicine 2025 55 2

Article usage

Article usage: September 2023 to April 2025

AbstractFullPdf
Sep 20231213916340
Oct 2023243365113
Nov 2023736716205
Dec 202313531389
Jan 202411840286
Feb 20248642484
Mar 20246034081
Apr 20246524251
May 20244121266
Jun 20244225859
Jul 20243735390
Aug 20243532174
Sep 20243714454
Oct 20243520468
Nov 20243316046
Dec 20242312740
Jan 20251814353
Feb 20251814935
Mar 20252312034
Apr 20251419847
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (11)
Journal of Nuclear Medicine
Vol. 64, Issue 11
November 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
Stefan A. Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L. Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, Jeremie Calais, Hans-Ulrich Kauczor, Dirk Jaeger, Juergen Debus, Uwe Haberkorn, Frederik L. Giesel
Journal of Nuclear Medicine Nov 2023, 64 (11) 1712-1720; DOI: 10.2967/jnumed.123.266046

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
Stefan A. Koerber, Manuel Röhrich, Leon Walkenbach, Jakob Liermann, Peter L. Choyke, Christoph Fink, Cathrin Schroeter, Anna-Maria Spektor, Klaus Herfarth, Thomas Walle, Jeremie Calais, Hans-Ulrich Kauczor, Dirk Jaeger, Juergen Debus, Uwe Haberkorn, Frederik L. Giesel
Journal of Nuclear Medicine Nov 2023, 64 (11) 1712-1720; DOI: 10.2967/jnumed.123.266046
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors
  • Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions
  • Google Scholar

More in this TOC Section

  • Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein–Targeted Imaging—FAP-RADS Version 1.0
  • Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study
  • Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials
Show more Clinical Investigation

Similar Articles

Keywords

  • FAPI
  • PET/CT
  • management
  • staging
  • radiation therapy
SNMMI

© 2025 SNMMI

Powered by HighWire